August 2024 digest

Which research priorities for AD in 2024?

Curative precision medicine vs preventive exposome-targeted medicine.

Dear Colleagues, Dear Friends,

In a recently published provocative perspective paper (DOI: 10.3389/fpubh.2024.1351732), Ian A. Myles, a NIH researcher, asks some good questions to our community which could help shaping our priorities.

Currently, with the industry-led dramatic development of biologics and targeted small molecules, mainstream thinking concentrates around precision medicine to find endotypes/biomarkers favoring best treatment options, in a curative perspective.

However, as for other complex/multifactorial diseases, this trend tends to neglect targeted prevention and thus to investigate what are the crucial shifts in the exposome which are truly causative of the immune-mediated inflammatory diseases, including AD and allergies.

If Myles’ perspective raises a controversy about the interpretation of biological findings or skin phenotypes in the context of ethnic ancestry and skin phototypes in AD, his most relevant point is truly: what is important, and where are we heading to if we stay mainstream?

As he aptly points out, failure to assess for environmental factors or social determinants of health to privilege improperly termed innate biology with possible involuntary racialist connotations is a dead end.

Doha meeting update

Register NOW!
-25% Early bird rates are extended to Sep 10!

The Call for abstracts results are available here.

With 160+ abstracts adjudicated including late-breaking abstracts, the program of the 14th Georg Rajka Symposium on AD (Doha, Qatar, October 24-26, 2024) is now being finalized. An update is available on our website. The ActaDV supplement with the abstracts will be available online at the opening of the meeting.

Best wishes,

Alain TAÏEB
President ISAD

---

#StayInformed: